Alaunos Therapeutics, Inc.
TCRT · Nasdaq · United States
Share price · TCRT
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when TCRT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 13 Oct 2026+188.6%
- 12 Oct 2026+33.6%
- 7 Oct 2026+12.9%
Nothing announced by TCRT that day or the session before.
- 2 Oct 2026-10.9%
Nothing announced by TCRT that day or the session before.
- 18 Sep 2026-25.0%
- 17 Sep 2026+25.0%
- 16 Sep 2026-9.2%
Nothing announced by TCRT that day or the session before.
- 29 Jun 2026+13.9%
- 11 Jun 2026+12.2%
Nothing announced by TCRT that day or the session before.
- 8 Jun 2026-12.3%
Nothing announced by TCRT that day or the session before.
Share of unusual movement by asset
For each asset, the share of TCRT's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 60% |
| Sessions with no dated event | — | 40% |
No dated announcements about its assets since 2 Jul 2024.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | apoptosis via reactive oxygen species (ROS) generation and mitochondrial disruptionSmall molecule | Non-Hodgkin Lymphoma Peripheral T-Cell Lymphoma |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $0 | $0.4M | $0.1M | $0.9M-$0.3M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | $0 | $0.4M | $0.3M | $1.0M-$1.0M operating cash flow | report ↗ |
| 2025-Q3 | $0 | $0.5M | $1.9M | $1.2M-$0.8M operating cash flow | report ↗ |
| 2025-Q2 | $0 | $0.2M | $2.9M | $1.1M-$0.7M operating cash flow | report ↗ |
| 2025-Q1 | $0 | $0.3M | $0.3M | $1.1M-$0.8M operating cash flow | report ↗ |
| 2024-Q3 | $0 | $0.1M | $1.7M | $1.1M-$0.8M operating cash flow | report ↗ |
| 2024-Q2 | $0 | $0.2M | $2.5M | $1.1M-$1.7M operating cash flow | report ↗ |
| 2024-Q1 | $0 | $0.1M | $4.1M | $1.7M-$1.9M operating cash flow | report ↗ |
| 2023-Q3 | $0 | $3.7M | $12M | $8.5M-$6.4M operating cash flow | report ↗ |
| 2023-Q2 | $0 | $5.2M | $18M | $8.8M-$7.0M operating cash flow | report ↗ |
| 2023-Q1 | $0 | $6.5M | $37M | $10M-$9.4M operating cash flow | report ↗ |
| 2022-Q3 | $2.9M | $7.9M | $52M | $8.8M-$6.1M operating cash flow | report ↗ |
| 2022-Q2 | $0 | $5.9M | $60M | $9.9M-$8.2M operating cash flow | report ↗ |
| 2022-Q1 | — | $5.6M | $68M | $9.8M-$7.8M operating cash flow | report ↗ |
| 2021-Q3 | $0.4M | $15M | $92M | $23M-$9.6M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | <$0.1M | $1.4M | $1.4M | $1.1M-$2.9M operating cash flow | report ↗ |
Alaunos Therapeutics, Inc. reported revenue of $0.01M, up 0.0% YoY, R&D spend of $1.36M, up 277.8% YoY, cash and equivalents of $1.39M, and a net loss of $4.18M for fiscal year 2025.
Figures only: this period's report disclosed no narrative text
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | <$0.1M | $0.4M | $1.1M | $1.2M-$5.0M operating cash flow | report ↗ |
| 2023-FY | <$0.1M | $16M | $6.1M | $8.8M-$30M operating cash flow | report ↗ |
| 2022-FY | $2.9M | $25M | $53M | $9.4M-$29M operating cash flow | report ↗ |
| 2021-FY | $0.4M | $50M | $76M | $20M-$61M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-06 | Jerman Michael Allen · director | Award / grant | 20,990 | $0.74 | $16K | Form 4 |
| 2026-10-06 | Postma Robert W · director | Award / grant | 21,829 | $0.74 | $16K | Form 4 |
| 2026-10-06 | Weis Holger · CEO | Award / grant | 23,564 | $0.74 | $18K | Form 4 |
| 2026-10-06 | Vieser Jaime · director | Award / grant | 22,669 | $0.74 | $17K | Form 4 |
| 2026-08-06 | Weis Holger · CEO | Award / grant | 4,363 | $2.01 | $9K | Form 4 |
| 2026-07-23 | Vieser Jaime · director | Award / grant | 8,789 | $1.92 | $17K | Form 4 |
| 2026-07-23 | Postma Robert W · director | Award / grant | 8,463 | $1.92 | $16K | Form 4 |
| 2026-07-23 | Weis Holger · CEO | Award / grant | 4,568 | $1.92 | $9K | Form 4 |